Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,582.69
(
0.11%
)
US TECH 100
23,392.00
(
0.08%
)
Dow Jones
46,504.67
(
-0.13%
)
Brent Oil
107.95
(
0.00%
)
Bitcoin
66,963.99
(
-0.49%
)
News Focus
News Focus
Post# of 257357
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122850
Boards Moderated 8
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 240393

Thursday, 11/18/2021 5:31:26 PM

Thursday, November 18, 2021 5:31:26 PM

Post# of 257357
Re: ENTA EDP-721

Discontinuing a compound is always a letdown, but it’s much better to find a safety problem in phase-1 than later on.

ENTA will need to find a second oral compound to complement EDP-514 (the lead HBV compound), which could either be another RNA destabilizer or a compound with a different MoA. The company’s drug-discovery engine is up to the task, IMO.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today